Expectedly, the patient group showing high HER2 expression (HER2-High group) had shorter PFS and OS compared with the low-HER2-expressing (HER2-Low group) patients with serous-histology ovarian cancer (Figure 5A–H). This evidence concerns the gene ERBB2 and ovarian carcinoma.